Ciclofilin Pharmaceuticals Inc., a hepatitis B virus ("HBV") drug developer, announced today the...
Sagent Pharmaceuticals, Inc., a leader of specialty pharmaceutical products with an emphasis on...
DelMar Pharmaceuticals, Inc., today announced that it has appointed biopharmaceutical industry veteran, Erich Mohr, Ph.D., R.Psych., to its Board of Directors as an independent director.
The Board of Directors of Sagent Pharmaceuticals has announced that Jeffrey Yordon, Chairman and Chief Executive Officer, has informed the Board of his decision to retire from the company.
Teva Pharmaceutical Industries has announced the appointment of Timothy R. Wright to the Company’s executive leadership team, heading business development, strategy and innovation.
Catalent Pharma Solutions has announced that Sharon Johnson, Senior Vice President, Global Quality & Regulatory Affairs, is to head up Catalent’s newly formed Quality, Product Development & Regulatory Affairs organization.
Dr. Nancy Snyderman said Thursday that she's leaving her job as chief medical editor for NBC News, six months after unleashing public anger for failing to observe a quarantine after covering the Ebola epidemic last fall.
Shares of Acadia Pharmaceuticals shed nearly a quarter of their value in premarket trading Thursday, a day after the drug developer announced the sudden retirement of its long-time CEO and said it will delay the regulatory submission for its most advanced product.
Merz North America has announced the appointment of Salisa Hauptmann as Vice President and Chief Compliance Officer. Hauptmann will be responsible for providing strategic and operational leadership to Merz on matters relating to compliance issues, including industry standards established by the Department of Health and Human Services, the Office of Inspector General, and other Federal and state agencies.
One of the nation's leading medical researchers joined the Food and Drug Administration on Monday, taking on the agency's No. 2 leadership job at a critical juncture for prescription drugs, medical devices and tobacco products.
PureTech, a science and technology R&D company focused on identifying, inventing and commercializing disruptive products and technologies in the healthcare sector, has announced the appointment of Christopher Viehbacher, former CEO and Member of the Board of Directors of Sanofi, to its Board of Directors.
Takeda Pharmaceutical Co., Japan's largest drug company, has expanded its Singapore operations by relocating its emerging markets business unit to the city-state from Zurich, executives said at an inauguration ceremony Wednesday.
Turing Pharmaceuticals AG announced its official launch today, along with news of three acquisitions for its commercial operations and development pipeline. The company also introduced its senior management team.
Alkermes has appointed Mark Namchuk, Ph.D., as Senior Vice President of Research, Pharmaceutical and Nonclinical Development. Dr. Namchuk will be responsible for advancing the company’s early-stage product pipeline.
Astellas has announced organizational and personnel changes in the Americas, highlighting the company's focus on international markets, while also building new Corporate Affairs and Corporate Development functions.
Sanofi said Thursday Brandicourt, 59, will start on April 2. He has been Bayer HealthCare's chairman and CEO since November 2013, and was also an executive for Pfizer Inc.
Horizon Pharma, a specialty biopharmaceutical company, today announced it has opened a Chicago office. The office, which is located at 150 South Wacker Drive, will primarily house commercial, corporate analytics and business development staff.
The company announced the overhaul of its HealthCare, CropScience and other operations in a letter sent to employees Wednesday, though it indicated specific decisions on what the company will look like next January haven't yet been made.
Sanofi SA acknowledged the job cuts in its Genzyme division Wednesday. The layoffs will largely effect facilities in Cambridge, with about 70 at the rare disease-focused Sanofi Genzyme Research and Development Center and 30 at a smaller cancer research center.
Catalent has appointed Thomas Castellano as Vice President Finance, Investor Relations, and Treasurer effective immediately. Mr. Castellano joined Catalent in 2008 when the Company formed its Financial Planning and Analysis (FP&A) group and was actively involved in building out its financial operations.
Margaret Hamburg told employees of the FDA in an email that the agency's chief scientist, Stephen Ostroff, will serve as acting commissioner. She is among the longest-serving commissioners to head the agency and helped oversee the creation of a new food safety system, reforms in how drugs are reviewed and new tobacco regulations.
The Advanced Medical Technology Association said the tax -- which was enacted as part of the Affordable Care Act to generate revenue for the law -- resulted in 4,500 job reductions in 2014.
Epizyme has announced that Robert A. Copeland, Ph.D., has been named President of Research. Dr. Copeland, who was previously Executive Vice President of Research and Chief Scientific Officer at Epizyme, will continue to serve as Chief Scientific Officer.
Alexion Pharmaceuticals announced that its Board of Directors has appointed David L. Hallal as the Company’s Chief Executive Officer (CEO), effective April 1, 2015. Mr. Hallal currently serves as Alexion’s Chief Operating Officer (COO) and is a Director of the Board.
U.S. Food and Drug Administration Commissioner Margaret A. Hamburg, M.D., has appointed Robert Califf, M.D., a recognized global leader in cardiology, clinical research, and medical economics, as FDA Deputy Commissioner for Medical Products and Tobacco.
The Pharma & Biopharma Outsourcing Association (PBOA) today announced that Nelson Patterson, Vice President, Sales and Marketing at Baxter BioPharma Solutions, has been elected to its Board of Trustees, effective immediately. Mr. Patterson was elected after Baxter BioPharma Solutions joined the PBOA as a Sustaining Member.
- Page 1